• Anti-b Suppresses mTOR Signaling to Treat Hyperlipidaemia an

  2026-04-30

  This study demonstrates that Anti-b, a novel small molecule, effectively reduces hyperlipidaemia and hepatic steatosis in rodent models by targeting the mTOR/PPARγ and mTOR/SREBP1 signaling pathways. The work offers mechanistic insight into mTOR modulation as a therapeutic avenue for lipid metabolism disorders and highlights potential translational applications for metabolic disease research.

• Entecavir (BMS200475): Advanced Protocols for HBV Replicatio

  2026-04-30

  Entecavir (BMS200475) is a benchmark compound for selective hepatitis B virus replication inhibition, excelling in both wild-type and lamivudine-resistant models. This article delivers protocol enhancements, troubleshooting strategies, and applied research insights to maximize reproducibility and translational value in chronic hepatitis B workflows.

• mRNA Nanovaccine Targeting GPC3-HSP70 Enhances Immunity in H

  2026-04-29

  This study introduces a novel mRNA nanovaccine encoding repeated GPC3127−136 epitopes fused to HSP70, designed for targeted immunotherapy against hepatocellular carcinoma (HCC). The nanovaccine, when combined with anti-PD-L1 therapy, showed potent synergistic enhancement of T-cell-mediated antitumor immunity, suggesting a promising strategy for advanced HCC treatment.

• Thiazovivin: ROCK Inhibitor for Stem Cell Survival and Repro

  2026-04-29

  Thiazovivin is a ROCK inhibitor optimized for improving human embryonic stem cell survival and enhancing the induction of pluripotent stem cells during reprogramming workflows. It is not intended for diagnostic, therapeutic, or clinical uses, and its application is limited to in vitro research requiring controlled modulation of ROCK signaling.

• Strategic Cell Proliferation Analysis: EdU Imaging in Transl

  2026-04-28

  This thought-leadership article explores how EdU Imaging Kits (HF594) enable translational researchers to bridge mechanistic insight and clinical utility in cell proliferation assays. Integrating recent breakthroughs in overcoming drug resistance in adenocarcinoma and advanced click chemistry detection, the article highlights strategic considerations for optimizing DNA synthesis measurement, benchmarking best practices, and extending the impact of S-phase analysis in preclinical and translational workflows. By contextualizing the APExBIO EdU Imaging Kit’s mechanistic advantages and evidentiary underpinnings, we chart a forward-thinking path for accelerating therapeutic innovation.

• Extracellular Vesicle ACLY Drives TAM Differentiation in HCC

  2026-04-28

  This study reveals that hepatocellular carcinoma (HCC) cells secrete extracellular vesicles (EVs) containing ATP-citrate lyase (ACLY), which are selectively taken up by monocytes, driving their differentiation into immunosuppressive tumor-associated macrophages (TAMs). Targeting EV-transferred ACLY in TAMs offers a promising avenue to enhance immunotherapy in HCC.

• Cefotaxime: Third-Generation Cephalosporin in Resistance Res

  2026-04-27

  Cefotaxime empowers researchers to dissect antimicrobial resistance mechanisms and model infections with precision, thanks to its broad spectrum and beta-lactamase stability. This guide offers actionable workflows, troubleshooting insights, and real-world protocol optimizations for leveraging Cefotaxime in experimental setups.

• EdU Imaging Kits (HF594): Unraveling Treg Cell Proliferation

  2026-04-27

  Explore the advanced capabilities of EdU Imaging Kits (HF594) for quantifying cell proliferation and DNA synthesis measurement, with a unique focus on Treg cell dynamics in asthma. Discover how this assay transforms translational immunology research.

• RAB31 Drives ESCRT-Independent Exosome Biogenesis via Flotil

  2026-04-26

  This study delineates a novel, ESCRT-independent exosome biogenesis pathway regulated by RAB31, which is activated by EGFR. RAB31 orchestrates intraluminal vesicle formation and prevents lysosomal degradation of multivesicular endosomes, reshaping our understanding of protein sorting and secretion in cell biology.

• Tobramycin: Benchmarks, Mechanism, and Research Integration

  2026-04-25

  Tobramycin is a water-soluble aminoglycoside antibiotic with a broad spectrum against Gram-negative bacteria. Its validated purity and precise mechanism make it an essential tool in microbiology and antibiotic resistance research. This dossier provides quantitative, evidence-backed insights for scientific workflows.

• Foretinib (GSK1363089): Optimizing In Vitro Cancer Drug Resp

  2026-04-24

  Explore how Foretinib (GSK1363089) advances in vitro cancer drug response assays by integrating precise growth inhibition metrics and practical workflow insights. This article uniquely bridges mechanistic depth with protocol optimization for reproducible research.

• ATRX-Deficient Glioma Sensitivity to RTK and PDGFR Inhibitor

  2026-04-24

  This study identifies increased sensitivity of ATRX-deficient high-grade glioma cells to receptor tyrosine kinase (RTK) and PDGFR inhibitors. These findings suggest ATRX mutation status could inform targeted therapy strategies and clinical trial design in aggressive gliomas.

• Nicotinamide Adenine Dinucleotide (NAD+): Mechanisms & Limit

  2026-04-23

  Nicotinamide Adenine Dinucleotide (NAD+) functions as a central redox coenzyme and signaling substrate in metabolic and autophagy pathways. Recent evidence revises the role of AMPK in autophagy regulation, impacting experimental design for NAD+-dependent assays. This article presents actionable, evidence-based guidance for integrating NAD+ in metabolic research.

• Meropenem Trihydrate: Precision Benchmarking in Resistance P

  2026-04-23

  Explore how Meropenem trihydrate enables precision benchmarking and deep phenotyping in antibiotic resistance studies. This article uniquely dissects metabolomics-driven insights for research design, offering advanced guidance for microbiology and pharmacology innovation.

• Epinephrine Bitartrate in Translational Research: Mechanisms

  2026-04-22

  This thought-leadership article explores the mechanistic underpinnings, translational potential, and strategic deployment of (-)-Epinephrine (+)-bitartrate (L-Epinephrine Bitartrate) in cardiovascular, sympathetic nervous system, and neurobiology research. Leveraging both primary literature and advanced protocol insights, it connects foundational adrenergic receptor biology to emerging paradigms in experimental design and clinical translation. The article highlights APExBIO’s product leadership while offering actionable guidance for researchers aiming to maximize reproducibility and relevance in their work.

16237 records 1/1083 page Next 12345 下5页 Last page